ArticleOphthalmology2025
Delayed Rod-Mediated Dark Adaptation Is Associated with Incidence and Early Progression of Age-Related Macular Degeneration: Alabama Study on Early Age-Related Macular Degeneration 2.
Article in Ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Revisiting retinal and macular degeneration in the genomics era.Nature reviews. Genetics · 2026Review
- Longitudinal Assessment of Low Luminance Questionnaire Scores in Early and Intermediate AMD.Investigative ophthalmology & visual science · 2026Observational
- Xanthophyll Carotenoid Intake, Plasma Levels, and Retinal Visualization in Aging and Age-Related Macular Degeneration: ALSTAR2.Investigative ophthalmology & visual science · 2026Article
- Impaired Rod-Mediated Vision is the Functional Hallmark of Ageing and Early and Intermediate Age-Related Macular Degeneration.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Article
- Minimum set of outcome measures for non-advanced age-related macular degeneration: a Delphi consensus statement by the TRACER (intermediate age-related macular degeneration) study group.The British journal of ophthalmology · 2026Article
- Visible Light Optical Coherence Tomography Reveals Aging at the Retinal Pigment Epithelium-Bruch's Membrane Interface.bioRxiv : the preprint server for biology · 2026Article
- The Science of Rod-Mediated Dark Adaptation, an Outcome Measure for Age-Related Macular Degeneration: The 2025 Proctor Medal Lecture.Investigative ophthalmology & visual science · 2026Article
- Introducing Christine A. Curcio and Cynthia Owsley, the 2025 Recipients of the Proctor Medal.Investigative ophthalmology & visual science · 2026Article
- Choriocapillaris Flow Signal Deficits Are Associated With AMD Onset and Early Progression Over Three Years: ALSTAR2 Follow-Up.Investigative ophthalmology & visual science · 2026Article
- Natural History of Visual Function Changes Over Three Years in Normal Aging and in Early and Intermediate Age-Related Macular Degeneration: ALSTAR2.Translational vision science & technology · 2026Article
- Hypertransmission and Vision in Aging and Age-Related Macular Degeneration: Longitudinal Data From ALSTAR2.American journal of ophthalmology · 2025Article
- Total Retinal Pigment Epithelium Thickness and Reflectivity, in Relation to Histology and Vision, at the Aging-AMD Transition: ALSTAR2 Baseline.Investigative ophthalmology & visual science · 2025Article
Corrections and comments
- Erratum issuedCorrigendum.2026
Authors and funding
8 authors.
Funding
Abstract
purposeTo examine whether delayed rod-mediated dark adaptation (RMDA) in healthy older eyes and those with early age-related macular degeneration (AMD) is associated with AMD incidence and progression at follow-up, as compared with other visual functions reliant on rods, cones, or mixed rod-cone mediation.
designLongitudinal study over 3 years.
participantsEyes from adults ≥60 years of age with normal macular health or with early AMD at baseline.
methodsAt baseline, eyes underwent fundus photography to establish AMD presence and severity using the Age-Related Eye Disease Study (AREDS) 9-step classification system. The following visual functions were tested in 1 eye at baseline (the study eye): RMDA, scotopic sensitivity, low-luminance acuity, mesopic contrast sensitivity, mesopic light sensitivity, visual acuity, and contrast sensitivity. Three years later at follow-up, fundus photography and the AREDS classification were repeated. Age-adjusted relative risks and 95% confidence intervals measured the association between visual functions and AMD incidence and progression for the study eye and the fellow eye at follow-up.
main outcome measuresPresence and severity of AMD at the 3-year follow-up visit in the study and fellow eyes.
resultsHealthy older eyes at baseline with delayed RMDA were 3.54 or 3.40 times more likely to have incident AMD at the 3-year follow-up in the study eye and the fellow eye, respectively, compared with eyes without delays. No other visual functions were associated with AMD incidence, except for low-luminance visual acuity in the study eye. Eyes with early AMD at baseline with delayed RMDA were 3.89 or 2.65 times more likely to have progressed at follow-up for the study and fellow eye, respectively. No other visual functions were associated with AMD progression at follow-up.
conclusionsRod-mediated dark adaptation is the only visual function of those tested that was associated with AMD incidence and progression over 3 years in healthy eyes or those with early AMD at baseline. Our results suggest that other visual functions are not useful for understanding AMD incidence and early progression risk. Interventions that eventually are designed to arrest early AMD progression or preventative measures in those at risk should consider RMDA a functional outcome measure. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.